Some consider the number 13 unlucky; fear of the number has its own name, "triskaidekaphobia." So it is perhaps somewhat fitting that day 13 of our ASCO Odyssey is dedicated to the cancer type with which scientists and doctors have had arguably the least luck in treating: central nervous system cancers. We still await CNS oncology's immunotherapy or EGFR/ALK moment, and unfortunately, as of ASCO 2024, that has not come yet. However, that has not stopped legions of incredibly dedicated and intelligent people from trying. ASCO 2024 brought us several very interesting studies, both in form and function, that we hope will lay the groundwork for that magical breakthrough in this very difficult group of cancers.

Links to studies discussed in this episode (subscription may be required)

A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas. Link

Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Link

N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Link

Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations. Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.